Other OVs, like engineered HSV-1 and influenza A viruses, have shown enhanced antitumor responses when combined with ipilimumab, primarily by increasing immune cell infiltration (CD4+, CD8+ T cells) and reducing immunosuppressive Tregs in the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.